Evommune, Inc. (EVMN) AI Stock Analysis

• Market Cap: $848.59M
• Dividend Yield: N/A
• Average Volume (3M): 935.27K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.84
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 36,018,370
• 10 Day Avg. Volume: 412,591
• 30 Day Avg. Volume: 935,274
• PEG Ratio: 1.98
• Price to Book (P/B): 2.63
• Price to Sales (P/S): 41.51
• P/FCF Ratio: -7.04
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 20.68
• Enterprise Value/Gross Profit: 23.15
• Enterprise Value/Ebitda: -3.90
• 1Y Price Target: $49.25
• Price Target Upside: 58.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $22.00 ▼(-29.26% Downside)
• Action: Reiterated Date: 03/09/26
• Date: Action: Reiterated 03/09/26

The score is held back primarily by ongoing large losses and worsening cash burn despite strong revenue growth and a significantly improved balance sheet. Technicals add modest support (positive MACD and price above the 50-day average), while valuation remains pressured by negative earnings and no dividend support.

Positive Factors

Revenue Growth Trajectory

Evommune's multi-year revenue increase from $5M to $13M demonstrates durable top-line traction and growing commercial or collaboration uptake. Sustained revenue scaling improves prospects for leveraging fixed R&D and SG&A, helping unit economics as clinical programs convert to broader indications and market penetration.

Material Balance Sheet Strengthening

A dramatic recapitalization and sharply reduced leverage materially lower insolvency and refinancing risk, providing durable financial flexibility. Stronger equity and higher assets support multi-year clinical investment, partnership options, and buffer operational volatility typical in biotech development cycles.

Clinical Validation and Pipeline Momentum

Phase 2a proof-of-concept for EVO301 validates IL-18 inhibition and de-risks a lead program structurally. Statistically significant efficacy, safety and biomarker reductions support progression to Phase 2b and broader indications, strengthening long-term commercial potential and strategic partnering or licensing options.

Negative Factors

Large Persistent Net Losses

Sustained multi-year net losses indicate the company remains far from operating profitability; this structural loss profile pressures long-term margins and requires consistent funding or rapid scale-up. Without demonstrated path to margin improvement, losses constrain strategic choices and investor returns.

Accelerating Negative Cash Generation

Worsening operating and free cash flow over successive years shows rising burn and negative cash conversion. This persistent, increasing outflow creates structural financing needs and raises execution risk: the company must either increase revenue materially or cut spend to avoid repeated dilutive capital raises.

Dependence on External Financing

Reliance on a large private placement to fund operations underscores dependence on external capital. While it extends runway, it creates dilution risk and makes long-term viability contingent on clinical success or future financings, a structural vulnerability until programs generate sustainable revenues.

Evommune, Inc. Business Overview & Revenue Model

Company Description

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

How the Company Makes Money

null

Evommune, Inc. Financial Statement Overview

Summary

Revenue is scaling quickly ($5.0M in 2023 to $13.0M in 2025) and the 2025 balance sheet is materially stronger (debt down to $2.1M and equity up to $205.6M). However, profitability and cash generation remain very weak with large, persistent net losses (-$68.9M in 2025) and accelerating cash burn (operating cash flow -$76.4M; free cash flow -$76.7M in 2025), keeping the score below average.

Income Statement

Revenue has increased meaningfully (from $5.0M in 2023 to $7.0M in 2024 to $13.0M in 2025), and gross profit remains strong on the reported revenue base. However, profitability is very weak: operating losses and net losses are large and persistent (net income of -$34.1M in 2023, -$66.8M in 2024, and -$68.9M in 2025), indicating the cost structure is far ahead of current scale. Overall, the top-line trajectory is a positive, but the magnitude and persistence of losses keep the score low.

Balance Sheet

The balance sheet shows a dramatic improvement year-over-year: debt fell sharply from $193.3M (2024) to $2.1M (2025), while equity swung from negative (-$144.2M in 2024) to strongly positive ($205.6M in 2025), alongside higher total assets ($224.9M in 2025 vs. $76.1M in 2024). This suggests a major recapitalization and significantly reduced leverage risk. The key weakness is that the business is still loss-making, so sustaining this strengthened balance sheet depends on ongoing funding discipline and progress toward lower cash burn.

Cash Flow

Cash generation is a clear concern: operating cash flow and free cash flow are deeply negative across all periods and have worsened in dollar terms (operating cash flow from -$30.0M in 2023 to -$58.2M in 2024 to -$76.4M in 2025; free cash flow from -$30.1M in 2023 to -$58.3M in 2024 to -$76.7M in 2025). While cash burn is not unusual in biotechnology, the direction of travel implies higher financing needs unless expenses are reduced or revenue scales faster. This heavy and rising cash outflow drives a low score.

Breakdown	Dec 2025	Dec 2024	Dec 2023
Income Statement
Total Revenue	13.00M	7.00M	5.00M
Gross Profit	11.61M	5.71M	4.00M
EBITDA	-79.68M	-65.49M	-32.99M
Net Income	-68.87M	-66.81M	-34.05M
Balance Sheet
Total Assets	224.95M	76.06M	82.25M
Cash, Cash Equivalents and Short-Term Investments	149.20M	72.04M	79.08M
Total Debt	2.06M	193.31M	150.63M
Total Liabilities	19.38M	220.29M	159.96M
Stockholders Equity	205.57M	-144.24M	-77.71M
Cash Flow
Free Cash Flow	-76.68M	-58.28M	-30.09M
Operating Cash Flow	-76.44M	-58.20M	-29.97M
Investing Cash Flow	-115.31M	-3.99M	-48.43M
Financing Cash Flow	220.76M	49.42M	63.75M

Evommune, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIR	63 Neutral	$1.50B	-1.91	-49.31%	―	-78.55%	7.74%
OCGN	55 Neutral	$734.49M	-5.95	-2626.38%	―	14.26%	-23.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARCT	50 Neutral	$191.00M	-1.44	-27.43%	―	-41.53%	-11.32%
EVMN	49 Neutral	$848.59M	-7.84	89.72%	―	―	―
ALT	49 Neutral	$444.84M	-3.61	-49.35%	―	-61.54%	31.25%
VALN	48 Neutral	$895.97M	-5.03	-58.93%	―	14.86%	-1440.45%

Evommune, Inc. Corporate Events

Evommune Reports Q4 2025 Results and Pipeline Progress

Evommune, Inc. reported its fourth quarter and full-year 2025 results on March 5, 2026, highlighting positive Phase 2a proof-of-concept data for its injectable IL-18 binding protein fusion protein EVO301 in moderate-to-severe atopic dermatitis, with meaningful efficacy after two doses and a favorable safety profile. The company also advanced its first-in-class oral MRGPRX2 antagonist EVO756 with ongoing Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis, expanded its cash position to a projected runway through 2028 via a $125 million private placement and collaboration revenue, and posted a 2025 net loss of $68.9 million as it increased R&D and G&A spending to support its growing clinical pipeline and indication expansion plans.

The most recent analyst rating on (EVMN) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Evommune, Inc. stock, see the EVMN Stock Forecast page.

Evommune Announces $125 Million Private Placement Financing

On February 12, 2026, Evommune, Inc. entered into a securities purchase agreement to sell 4,494,279 shares of its common stock at $27.88 per share in a private placement to a select group of new and existing mutual funds and dedicated healthcare institutional investors, for expected gross proceeds of approximately $125 million. The private placement, which relies on a registration exemption and is expected to close around February 17, 2026, will see Evommune use the net proceeds to advance its clinical development programs and for general corporate purposes, supported by a registration rights agreement to facilitate future resale of the shares.

The most recent analyst rating on (EVMN) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Evommune, Inc. stock, see the EVMN Stock Forecast page.

Evommune Advances EVO301 After Positive Phase 2a Results

On Feb. 10, 2026, Evommune reported positive top-line data from a randomized, double-blind, placebo-controlled Phase 2a trial of its long-acting fusion protein EVO301 in 70 adults with moderate-to-severe atopic dermatitis. The intravenous regimen met its primary EASI-based efficacy endpoint with a 33% placebo-adjusted improvement at week 12, showed rapid statistically significant EASI reductions at weeks 4, 8 and 12, and achieved vIGA-AD 0/1 in 23% of treated patients versus none on placebo.

EVO301 demonstrated a favorable safety profile with no related serious or severe adverse events, no treatment-related discontinuations, pharmacokinetics consistent with a once-every-four-weeks dosing schedule, and robust reductions in Th2 and non-Th2 inflammatory biomarkers. The strong proof-of-concept results validate IL-18 inhibition as a therapeutic strategy, support Evommune’s plan to advance EVO301 into a Phase 2b dose-ranging trial and explore additional indications such as ulcerative colitis, and reinforce the company’s ambitions to expand its presence in the immunology space.

The most recent analyst rating on (EVMN) stock is a Sell with a $17.00 price target. To see the full list of analyst forecasts on Evommune, Inc. stock, see the EVMN Stock Forecast page.